REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $7.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2025-03-14
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $400.00K, a 300.00% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-06-30 was $2.70M, a 8.00% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $2.00K, a 5.26% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $7.80M, a 65.96% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $4.70M, a 51.61% increase from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $3.10M, a 3.33% increase from fiscal 2021.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $3.00M, a 7.14% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $7.80M 10-K · filed 2025-03-14 | |||||||
| 2023-12-31 | $4.70M 10-K · filed 2025-03-14 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $400.00K derived: sum of 2 quarters · filed 2025-03-14 | $3.10M derived: sum of 3 quarters · filed 2025-03-14 | $3.10M 10-K · filed 2025-03-14 | ||||
| 2022-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.10M derived: sum of 2 quarters · filed 2022-11-01 | $3.10M 10-Q · filed 2022-11-01 | $3.50M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $2.70M 10-Q · filed 2022-08-02 | $3.10M derived: sum of 3 quarters · filed 2024-11-18 | $3.20M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-03-31 | $2.00K 10-Q · filed 2022-04-27 | $402.00K derived: sum of 2 quarters · filed 2024-11-18 | $502.00K derived: sum of 3 quarters · filed 2024-11-18 | $3.00M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2021-12-31 | $400.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $500.00K derived: sum of 2 quarters · filed 2024-11-18 | $3.00M derived: sum of 3 quarters · filed 2024-11-18 | $3.00M 10-K/A · filed 2024-11-18 | ||||
| 2021-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $2.60M derived: sum of 2 quarters · filed 2022-11-01 | $2.60M 10-Q · filed 2022-11-01 | $2.80M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $2.50M 10-Q · filed 2022-08-02 | $2.70M derived: sum of 3 quarters · filed 2023-02-22 | $2.80M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $1.90K 10-Q · filed 2022-04-27 | $1.90M 10-Q · filed 2021-05-04 | $201.90K derived: sum of 2 quarters · filed 2023-02-22 | $301.90K derived: sum of 3 quarters · filed 2023-02-22 | $801.90K derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $300.00K derived: sum of 2 quarters · filed 2023-02-22 | $800.00K derived: sum of 3 quarters · filed 2023-02-22 | $2.80M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $600.00K derived: sum of 2 quarters · filed 2021-10-28 | $2.60M 10-Q · filed 2021-10-28 | $2.80M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $2.50M 10-Q · filed 2020-07-30 | $2.70M derived: sum of 3 quarters · filed 2022-02-17 | $2.90M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-04 | $2.20M derived: sum of 2 quarters · filed 2022-02-17 | $2.40M derived: sum of 3 quarters · filed 2022-02-17 | $2.90M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $400.00K derived: sum of 2 quarters · filed 2022-02-17 | $900.00K derived: sum of 3 quarters · filed 2022-02-17 | $3.10M 10-K · filed 2022-02-17 | ||||
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $700.00K derived: sum of 2 quarters · filed 2020-11-05 | $2.90M 10-Q · filed 2020-11-05 | $3.10M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $2.70M 10-Q · filed 2020-07-30 | $2.90M derived: sum of 3 quarters · filed 2021-02-24 | $3.20M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $2.20M 10-Q · filed 2020-05-06 | $2.40M derived: sum of 2 quarters · filed 2021-02-24 | $2.70M derived: sum of 3 quarters · filed 2021-02-24 | $3.20M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $500.00K derived: sum of 2 quarters · filed 2021-02-24 | $1.00M derived: sum of 3 quarters · filed 2021-02-24 | $2.30M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $800.00K derived: sum of 2 quarters · filed 2019-10-31 | $2.10M 10-Q · filed 2019-10-31 | $2.11M 10-Q · filed 2018-11-01 | $2.23M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $1.80M 10-Q · filed 2019-08-01 | $1.78M 10-Q · filed 2018-08-02 | $1.93M derived: sum of 3 quarters · filed 2020-02-26 | $2.27M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-03-31 | $1.30M 10-Q · filed 2019-05-09 | $1.34M 10-Q · filed 2018-05-08 | $1.43M derived: sum of 2 quarters · filed 2020-02-26 | $1.77M derived: sum of 3 quarters · filed 2020-02-26 | $2.31M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2017-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $466.00K derived: sum of 2 quarters · filed 2020-02-26 | $1.00M derived: sum of 3 quarters · filed 2020-02-26 | $2.20M 10-K · filed 2020-02-26 | $2.22M 10-K · filed 2018-02-22 | |||
| 2017-09-30 | $340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $879.00K derived: sum of 2 quarters · filed 2018-11-01 | $2.07M 10-Q · filed 2018-11-01 | $2.18M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $1.73M 10-Q · filed 2018-08-02 | $1.84M derived: sum of 3 quarters · filed 2019-03-01 | $2.24M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $1.20M 10-Q · filed 2018-05-08 | $1.30M derived: sum of 2 quarters · filed 2019-03-01 | $1.70M derived: sum of 3 quarters · filed 2019-03-01 | $2.25M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $505.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.05M derived: sum of 3 quarters · filed 2019-03-01 | $1.70M 10-K · filed 2019-03-01 | $1.71M 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $945.00K derived: sum of 2 quarters · filed 2017-11-09 | $1.59M 10-Q · filed 2017-11-09 | $2.90M 10-Q · filed 2016-11-03 | $1.26M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-06-30 | $550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.20M 10-Q · filed 2017-08-03 | $2.40M 10-Q · filed 2016-08-04 | $869.00K derived: sum of 3 quarters · filed 2018-02-22 | $1.21M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-03-31 | $645.00K 10-Q · filed 2017-05-04 | $1.39M 10-Q · filed 2016-05-05 | $319.00K derived: sum of 2 quarters · filed 2018-02-22 | $659.00K derived: sum of 3 quarters · filed 2018-02-22 | $1.51M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2015-12-31 | -$326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $14.00K derived: sum of 2 quarters · filed 2018-02-22 | $865.00K derived: sum of 3 quarters · filed 2018-02-22 | $1.54M 10-K · filed 2018-02-22 | $2.32M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.19M derived: sum of 2 quarters · filed 2016-11-03 | $1.86M 10-Q · filed 2016-11-03 | $1.59M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $851.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.52M 10-Q · filed 2016-08-04 | $1.52M 10-Q · filed 2015-08-06 | $1.25M derived: sum of 3 quarters · filed 2017-02-23 | $1.63M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $671.00K 10-Q · filed 2016-05-05 | $670.92K 10-Q · filed 2015-05-08 | $399.00K derived: sum of 2 quarters · filed 2017-02-23 | $775.68K derived: sum of 3 quarters · filed 2017-02-23 | $1.08M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | -$272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $104.68K derived: sum of 2 quarters · filed 2017-02-23 | $407.33K derived: sum of 3 quarters · filed 2017-02-23 | $751.00K 10-K · filed 2017-02-23 | $1.08M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $376.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $679.33K derived: sum of 2 quarters · filed 2015-11-05 | $1.02M 10-Q · filed 2015-11-05 | $1.02M 10-Q · filed 2014-11-07 | $1.08M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $302.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $646.32K 10-Q · filed 2015-08-06 | $703.04K derived: sum of 3 quarters · filed 2016-02-25 | $941.53K derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $343.67K 10-Q · filed 2015-05-08 | $400.39K derived: sum of 2 quarters · filed 2016-02-25 | $638.87K derived: sum of 3 quarters · filed 2016-02-25 | $1.10M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $56.72K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $295.20K derived: sum of 2 quarters · filed 2016-02-25 | $758.38K derived: sum of 3 quarters · filed 2016-02-25 | $991.00K 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $238.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $701.66K derived: sum of 2 quarters · filed 2014-11-07 | $934.28K 10-Q · filed 2014-11-07 | $1.11M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-06-30 | $463.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $695.79K 10-Q · filed 2014-08-11 | $870.35K derived: sum of 3 quarters · filed 2015-03-17 | $1.12M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-03-31 | $232.62K 10-Q · filed 2014-05-09 | $407.17K derived: sum of 2 quarters · filed 2015-03-17 | $661.44K derived: sum of 3 quarters · filed 2015-03-17 | |||||
| 2012-12-31 | $174.56K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $428.82K derived: sum of 2 quarters · filed 2015-03-17 | $931.00K 10-K · filed 2015-03-17 | |||||
| 2012-09-30 | $254.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $756.44K 10-Q · filed 2013-11-08 | ||||||
| 2012-06-30 | $502.18K 10-Q · filed 2013-08-07 | |||||||
| 2011-12-31 | $804.00K 10-K · filed 2014-03-14 | |||||||
| 2010-12-31 | $817.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |